Key Takeaways
- • Chinese drugmakers are turning to AI medical apps as a new channel to reach physicians after a graft crackdown restricted traditional hospital-based marketing, according to Reuters.
- • Alibaba Health is considering a model for its Hydrion app that would place promoted drug research and clinical evidence alongside AI-generated answers, similar to OpenEvidence, though it has not yet begun drugmaker collaboration.
- • Alibaba Health survey data shows 93% of the hundreds of doctors it polled now use AI tools, up from about 70% a year earlier.
- • Frost & Sullivan projects China's digital health marketing spending will grow at a 27.5% CAGR from 2027 to 2030, reaching 274.4 billion yuan ($41.1 billion), though it has no figures specific to physician-facing AI apps.
- • Null Hypothesis says major Chinese and foreign drugmakers have licensed its KnowS platform to build disease-specific physician academic platforms.
Summary
Drugmakers in China are seizing on a boom in AI-powered digital assistants as a potentially more efficient way to reach doctors, following a sweeping graft crackdown that disrupted traditional engagement channels, according to Reuters. A wave of apps similar to OpenEvidence, a ChatGPT-style tool designed for physicians that is not available in China, has entered the market this year from companies including Alibaba Health and JD Health. Drugmakers are exploring marketing arrangements with app makers or customizing platforms around specific diseases, executives told Reuters, after Beijing's increased scrutiny of hospital visits made doctor outreach harder and hurt sales.
Alibaba Health is considering a model for its Hydrion app in which promoted medical research and clinical evidence would appear alongside AI-generated responses to physician questions. Chief Technology Officer Wang Xiangzhi said drugmakers are central to that model, and that both domestic and foreign firms were "very, very" interested, although collaboration has not yet begun. Wang argued that if doctors gather on a single platform, pharmaceutical marketing budgets would shift online. Alibaba Health's survey found 93% of the hundreds of doctors it polled now use AI tools, up from around 70% a year earlier. Medical education firm PICA Health has integrated JD Health's AI-powered Zhiyi assistant and said in August it would offer drugmakers "targeted, grassroots-level digital academic promotion and physician education services."
The regulatory backdrop is a multiyear campaign against bribery in healthcare. Stricter measures issued this summer govern how pharma employees provide product information to doctors and hospitals. Zhejiang Xianju Pharmaceutical said in August the rules had affected sales, and a sales director at Xian Shijishengkang Pharmaceutical cited hospital visit restrictions as a key obstacle in July. Medlive Technology said in September that physician participation in academic activities was disrupted, yet it marketed 509 healthcare customer products in the first half of 2026, up about 14% year on year.
The market is still developing. Yidu Tech has had talks with drugmakers about marketing on its Yidu Evidence app, though an executive said the functionality is not yet offered and that drugmakers want more academic endorsements to rank higher in searches. Null Hypothesis CEO Gu Fei told Reuters that major Chinese and foreign drugmakers have licensed its KnowS platform to build disease-focused physician platforms, declining to name customers. Roche said it explores third-party medical AI tools for direct marketing to doctors, and Bayer said it monitors such technology for compliant physician engagement. The China Pharmaceutical Innovation and Research Development Association declined to comment. Frost & Sullivan estimates total enterprise digital health marketing spending in China, the world's second-largest pharmaceutical market, will reach 274.4 billion yuan ($41.1 billion) by 2030 at a 27.5% CAGR from 2027.
Alibaba Health is considering a model for its Hydrion app in which promoted medical research and clinical evidence would appear alongside AI-generated responses to physician questions. Chief Technology Officer Wang Xiangzhi said drugmakers are central to that model, and that both domestic and foreign firms were "very, very" interested, although collaboration has not yet begun. Wang argued that if doctors gather on a single platform, pharmaceutical marketing budgets would shift online. Alibaba Health's survey found 93% of the hundreds of doctors it polled now use AI tools, up from around 70% a year earlier. Medical education firm PICA Health has integrated JD Health's AI-powered Zhiyi assistant and said in August it would offer drugmakers "targeted, grassroots-level digital academic promotion and physician education services."
The regulatory backdrop is a multiyear campaign against bribery in healthcare. Stricter measures issued this summer govern how pharma employees provide product information to doctors and hospitals. Zhejiang Xianju Pharmaceutical said in August the rules had affected sales, and a sales director at Xian Shijishengkang Pharmaceutical cited hospital visit restrictions as a key obstacle in July. Medlive Technology said in September that physician participation in academic activities was disrupted, yet it marketed 509 healthcare customer products in the first half of 2026, up about 14% year on year.
The market is still developing. Yidu Tech has had talks with drugmakers about marketing on its Yidu Evidence app, though an executive said the functionality is not yet offered and that drugmakers want more academic endorsements to rank higher in searches. Null Hypothesis CEO Gu Fei told Reuters that major Chinese and foreign drugmakers have licensed its KnowS platform to build disease-focused physician platforms, declining to name customers. Roche said it explores third-party medical AI tools for direct marketing to doctors, and Bayer said it monitors such technology for compliant physician engagement. The China Pharmaceutical Innovation and Research Development Association declined to comment. Frost & Sullivan estimates total enterprise digital health marketing spending in China, the world's second-largest pharmaceutical market, will reach 274.4 billion yuan ($41.1 billion) by 2030 at a 27.5% CAGR from 2027.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.